The approval is based on findings from the CIRCUIT trial published in JAMA in October 2025.

Even within a few weeks of starting on Control-IQ by Tandem Diabetes Care, I knew that this new system that helps automate insulin dosing was the right choice and could help me better manage my ...

The FDA cleared an automated insulin delivery system for use by pregnant women with type 1 diabetes, according to an industry ...

Tandem Diabetes Care has announced that the U.S. Food and Drug Administration (FDA) has cleared Control-IQ+ automated insulin delivery (AID) technology for use in pregnancy complicated by ...

SAN DIEGO, Calif.--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today presented positive real-world data from ongoing use of ...

Tandem Diabetes (TNDM 0.54%) today announced the commercial launch of the newest version of its flagship insulin pump in the U.S. market. The company's signature t:slim X2 insulin pump will also now ...

Tandem Diabetes Care, Inc. TNDM recently presented data on real-world use of the t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology at the 14th International Conference on ...

Tandem Diabetes Care, Inc. TNDM presented positive real-world data, showing immediate and continued benefits across a diverse group of people using the t:slim X2 insulin pump with the Control-IQ ...

FDA clears Tandem Diabetes Care's Control-IQ+ automated insulin delivery technology for use in pregnancy for people with type ...

SAN DIEGO -- An automatic insulin delivery system bolstered type 1 diabetes outcomes even among users who didn't follow recommendations on boluses for meals and other corrections, according to a ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication of results from the Pediatric Artificial ...

Tandem Diabetes Care TNDM remained under pressure on Monday, after the company accounted for plans of a combined analysis of three trials of its Control-IQ technology. Tandem Diabetes Care’s margins ...